Wednesday, October 04, 2017 12:12:23 PM
On October 3, 2017, the Compensation Committee of the Board of Directors, after researching comparable companies and using a leading industry survey, recommended to the Board of Directors of Moleculin Biotech, Inc. (the “Company”), and after receiving the recommendation, the Board of Directors approved the following compensation arrangements with its named executive officers:
· Walter V. Klemp, Chief Executive Officer, was granted a cash bonus award of $93,000 and was issued a 10-year option to purchase 340,000 shares of the Company's common stock, under the Company's 2015 Stock Plan, with 4-year annual vesting (i.e., one-quarter of grant vests on the first, second, third and fourth anniversary of the issuance date) and an exercise price equal the closing price of the Company's common stock on the date of approval. Effective July 1, 2017, Mr. Klemp’s base compensation was increased to $350,000 for the compensation year ending May 30, 2018, his targeted cash bonus for such year was set at 50% of base compensation, and his targeted option grant value for such year was set at $800,000; provided that the cash bonus and option grants for the year are subject to Compensation Committee approval.
· Jonathan Foster, Chief Financial Officer, was granted a cash bonus award of $75,000 and was issued a 10-year option to purchase 145,000 shares of the Company's common stock, under the Company's 2015 Stock Plan, with 4-year annual vesting (i.e., one-quarter of grant vests on the first, second, third and fourth anniversary of the issuance date) and an exercise price equal the closing price of the Company's common stock on the date of approval. Effective July 1, 2017, Mr. Foster’s base compensation was increased to $300,000 for the compensation year ending May 30, 2018, his targeted cash bonus for such year was set at 43% of base compensation, and his targeted option grant value for such year was set at $450,000; provided that the cash bonus and option grants for the year are subject to Compensation Committee approval.
· Donald Picker, Chief Science Officer, was granted a cash bonus award of $50,000 and was issued a 10-year option to purchase 60,000 shares of the Company's common stock, under the Company's 2015 Stock Plan, with 4-year annual vesting (i.e., one-quarter of grant vests on the first, second, third and fourth anniversary of the issuance date) and an exercise price equal the closing price of the Company's common stock on the date of approval. Effective July 1, 2017, Dr. Picker’s base compensation will be $225,000 for the compensation year ending May 30, 2018, his targeted cash bonus for such year was set at 30% of base compensation, and his targeted option grant value for such year was set at $100,000; provided that the cash bonus and option grants for the year are subject to Compensation Committee approval.
In addition, on October 3, 2017, the Board approval the following policy for compensating non-employee members of the Board:
· Each non-employee director shall receive annual cash compensation of $35,000. In addition, the chair person of the Audit Committee, Compensation Committee and Nominating and Governance Committee shall receive an annual compensation of $15,000, $10,000 and $7,500, respectively; the other members of such committees shall receive an annual compensation of $7,500, $5,000 and $3,750, respectively; and the Lead Independent Director shall receive an annual compensation of $15,000. All payments will be made within 15 days after calendar quarter end.
· Upon the initial appointment (or election) of non-employee directors to the Board, the director will be issued a 10-year option to purchase 20,000 shares of the Company's common stock, under the Company's 2015 Stock Plan, with 3-year annual vesting and an exercise price equal the closing price of the Company's common stock on the date of the appointment (or election).
· Annually, on the date of the Company’s annual meeting, each non-employee director that is re-elected at the annual meeting will be issued, upon a motion and approval of the Board of Directors, a 10-year option to purchase 15,000 shares of the Company's common stock, under the Company's 2015 Stock Plan, with 3-year annual vesting and an exercise price equal the closing price of the Company's common stock on the date of the annual meeting.
Recent MBRX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:30:13 PM
- Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin • PR Newswire (US) • 05/09/2024 12:30:00 PM
- Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast • PR Newswire (US) • 05/08/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 12:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:13:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:55:19 PM
- Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data • PR Newswire (US) • 05/07/2024 12:55:00 PM
- Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024 • PR Newswire (US) • 05/02/2024 01:00:00 PM
- Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin • PR Newswire (US) • 05/01/2024 12:50:00 PM
- European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) • PR Newswire (US) • 04/18/2024 12:30:00 PM
- Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties • PR Newswire (US) • 04/10/2024 12:30:00 PM
- Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference • PR Newswire (US) • 03/28/2024 02:45:00 PM
- Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity • PR Newswire (US) • 03/27/2024 01:25:00 PM
- Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML • PR Newswire (US) • 03/27/2024 01:05:00 PM
- Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial • PR Newswire (US) • 03/25/2024 11:30:00 AM
- Moleculin Reports Full Year 2023 Financial Results • PR Newswire (US) • 03/22/2024 08:05:00 PM
- Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast • PR Newswire (US) • 03/20/2024 11:30:00 AM
- JPMorgan boosts dividends, Chipotle unveils 50:1 stock split, and Latest News • IH Market News • 03/20/2024 11:15:48 AM
- Moleculin Announces Reverse Stock Split • PR Newswire (US) • 03/19/2024 08:30:00 PM
- Moleculin to Present at the 36th Annual ROTH Conference • PR Newswire (US) • 03/12/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 02:30:15 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/16/2024 10:19:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 02:15:29 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM